Human insulin biosimilar - Marvel LifesciencesAlternative Names: Solumarv
Latest Information Update: 05 Oct 2016
At a glance
- Originator Marvel LifeSciences Private Limited
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Diabetes mellitus